Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2015, Article ID 367561, 5 pages
http://dx.doi.org/10.1155/2015/367561
Review Article

Cancer Cachexia and MicroRNAs

1Cancer Metabolism Research Group, Institute of Biomedical Sciences, University of São Paulo, Avenida Professor Lineu Prestes 1524, Cidade Universitária, 05508-000 São Paulo, SP, Brazil
2NAPmiR—miRNA Research Group, University of São Paulo, Avenida Professor Lineu Prestes 1524, Cidade Universitária, 05508-000 São Paulo, SP, Brazil
3Department of Clinical Surgery, University of São Paulo, Avenida Professor Lineu Prestes 2565, Cidade Universitária, 05508-000 São Paulo, SP, Brazil

Received 25 February 2015; Accepted 13 April 2015

Academic Editor: Yona Keisari

Copyright © 2015 Rodolfo Gonzalez Camargo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Cancer cachexia is a paraneoplastic syndrome compromising quality of life and survival, mainly characterized by involuntary weight loss, fatigue, and systemic inflammation. The syndrome is described as a result of tumor-host interactions characterized by an inflammatory response by the host to the presence of the tumor. Indeed, systemic inflammation is considered a pivotal feature in cachexia progression and maintenance. Cytokines are intimately related to chronic systemic inflammation and the mechanisms underlying the release of these factors are not totally elucidated, the etiology of cachexia being still not fully understood. Therefore, the understanding of cachexia-related mechanisms, as well as the establishment of markers for the syndrome, is very relevant. MicroRNAs (miRNAs) are a class of noncoding RNAs interfering with gene regulation. Different miRNA expression profiles are associated with different diseases and inflammatory processes. miRNAs modulate adipose and skeletal muscle tissue metabolism in cancer cachexia and also tumor and tissue derived inflammation. Therefore, we propose a possible role for miRNAs in the modulation of the host inflammatory response during cachexia. Moreover, the establishment of a robust body of evidence in regard to miRNAs and the mechanisms underlying cachexia is mandatory, and shall contribute to the improvement of its diagnosis and treatment.

1. Introduction

Cachexia is a wasting syndrome for which descriptions may be found as far as 2000 years ago [1], and is a consequence of cancer and other diseases, such as chronic obstructive lung disease, multiple sclerosis, congestive heart failure, tuberculosis, and AIDS, among others, with a high impact on quality of life [2]. In this review, we focus primarily on cancer cachexia, which affects approximately half of all patients with cancer. In advanced stages, this figure rises up to 80% [3, 4]. The condition compromises the responsiveness to cancer treatment and represents, per se, the direct cause of death of up to 20% of all patients [5].

The syndrome is characterized by unintentional significant reduction in body weight and, among other symptoms, reduced energy intake, fatigue, systemic inflammation, and metabolic abnormalities are frequently reported [6].

Despite the long search for etiologic factors underlying cachexia, and the fact that many scientific efforts have been devoted to its understanding, researchers agree that “we are still a long way from knowing the whole truth about the exact mechanisms behind its etiology” [7], which makes it very hard to diagnose and treat the syndrome, frustrating physicians and patients. The most widely accepted hypothesis is that cachexia would appear as the result of tumor-host interactions (Figure 1) [8], being deeply related to the increase and release of proinflammatory factors (Figure 2) [8, 9].

Figure 1: Traditional view of cachexia as discussed by Tisdale [8].
Figure 2: Emerging view of cachexia as proposed by Tisdale [8].

2. Cachexia Definition and Main Symptoms

Marked weight loss is the central symptom in many of the proposed diagnostic criteria [1012]. In 2011, a definition consensus for cachexia suggested the existence of different degrees of the syndrome. The syndrome would thus develop through three different and specific stages: precachexia, when anorexia and metabolic changes may be observed before weight loss; cachexia itself, with a weight loss ≥ 5% or BMI ≤ 20 and weight loss ≥ 2% or sarcopenia and weight loss > 2% and often reduced food intake and systemic inflammation; and, finally, refractory cachexia, in which survival expectance usually does not exceed three months [11].

3. Cachexia and Peripheral Tissues

In the wasting scenario in cancer cachexia neuroendocrine changes play an important part, provoking early satiety and aversion to food and leading to undernutrition [13]. These, combined with diminished food absorption and hypermetabolism, lead to a negative energy balance [14, 15] and contribute to the loss of mass, specially of adipose tissue and of skeletal muscle [16].

Nevertheless, peripheral tissues are highly affected by cachexia even before the presence of anorexia. Thus, the loss of adipose tissue and skeletal muscle mass precedes any decrease in food intake, which at the initial period of wasting can be normal or even increased [17, 18]. These tissues exhibit impaired homeostasis and altered metabolism, resulting in increased lipolysis in the adipose tissue and augmented proteolysis in the skeletal muscle. The white adipose tissue seems to be importantly adding to the inflammatory status in cachexia. Several studies showed that circulating levels of cytokines are altered in cachectic patients [1922]. These cytokines elicit an inflammatory response in the adipose tissue, which then releases chemoattractant proteins, which in turn will recruit immune cells from the blood stream; these cells infiltrate the tissue, provoking further release of proinflammatory mediators. As a consequence, lipolysis is activated, causing adipocytes and immune cells to secrete, in a vicious cycle, proinflammatory mediators such as tumor necrosis factor (TNF-alpha), interleukin- (IL-) 1β, interferon-gamma (INF-gamma), and IL-6. These cytokines may reach other tissues through the circulation and are associated with increased muscle catabolism and reduced muscle protein synthesis. On the other hand, the high concentration of circulating free fatty acids is sensed by the liver. This organ responds by increasing the uptake of these substrates, which, ultimately, may lead to the onset of steatosis and the induction of acute phase protein secretion. These changes contribute to the systemic onset of the so-called metabolic chaos.

4. miRNAs

Recently, changes in metabolism and in aspects of the inflammatory response have been found to be modulated by miRNAs, which are small noncoding RNAs of approximately 19–25 nucleotides (nt), known to be regulatory molecules for some of the most important levels of genome function, including chromatin structure, chromosome segregation, transcription, RNA processing, RNA stability, and translation [23].

These molecules are widely found in organisms including plants, nematodes, fruit flies, and mammals and are highly conserved among evolution [24]. miRNA biogenesis involves the transcription of genomic DNA by RNA polymerase II to produce primary miRNA transcripts (pri-miRNA). In sequence, the Drosha-DGCR8 RNase complex initiates miRNA maturation through the cleavage of a stem loop into the primary transcript. This generates a 60- to 70-nucleotide-long miRNA precursor, the “pre-miRNA,” characterized by the presence of an overhang of 2-3 nucleotides, still in the nucleus [25]. The newly produced pre-miRNA is then transported to the cytoplasm by exportin5 and processed to a double-stranded RNA molecule of about 19 to 25 nucleotides in length by yet another enzyme, the Dicer. Once incorporated into the effector complex miRISC (miRNA-induced silencing complex), one strand of the recently produced RNA molecule remains as a mature miRNA [26, 27], while the other strand may be either degraded, incorporated into another miRISC, or exported to the periphery by exosomes to exert its effects in a paracrine or endocrine way [28, 29]. The complex miRISC, together with the recently incorporated mature miRNA, acts directly on the mRNA to repress the translation of target genes by cleavage (perfect or near-perfect binding) or by forming a “hairpin” in the 3′UTR, through imperfect base pairing [30]. The binding site may also not be in the 3′UTR, but in the ORF or 5′UTR region of the target [31].

According to the miRBase [32], over 6,000 miRNA genes were identified in more than 223 known species, including viruses, plants, fungi, and animals. In humans, the number of miRNAs reaches up to 1500 (access in December 2014). Computational analysis estimates that more than 50% of human protein-coding genes are putatively regulated by miRNAs [33].

5. miRNAs, Peripheral Tissues, Cachexia, and Inflammation

The expression of miRNAs is highly dependent on tissue type, metabolic status, and presence of disease. Several studies describe miRNAs as important regulators of biological processes as cellular differentiation, proliferation, tissue development, and cell-type specific function and homeostasis. Nowadays, an increased number of diseases have been found to be associated with altered miRNAs expression [3436]. Several miRNAs have been studied and confirmed as having a role in inflammatory processes in peripheral tissues such as adipose tissue and muscle [37]. Moreover, there is strong evidence that miRNAs would function as an effective system that regulates the magnitude of inflammatory responses, by displaying effects on cellular development and aspects of cellular function [38].

miRNAs-modulated pathways in skeletal muscle have been extensively studied. Several highly expressed miRNAs are described in striated muscle: the “myomiRs.” miRNAs such as miR-1, miR-133a, miR133-b, miR-206, miR-208, miR208b, miR486, and miR-499 are part of this group and are associated with cell growth and differentiation, stress responsiveness, and protection against apoptosis [39, 40]. Muscle protein degradation in cachexia is mainly mediated by the ubiquitin proteasome system, which is induced through the activation of E3 ligases, atrogin-1/MAFbx, and MurF-1. The Forkhead box O (FoxO) signaling pathway participates in this process by the induction of the transcription of E3 ubiquitin ligases and has three members in skeletal muscle (FoxO1, FoxO3, and FoxO4). Muscle-specific overexpression of these proteins is described as sufficient to cause skeletal muscle atrophy in vivo; and inhibition of FoxO transcription activity prevents muscle fiber atrophy during cachexia [41]. Xu and colleagues verified that the miRNA-486 decreases FoxO1 protein expression and promotes FoxO1 phosphorylation to suppress E3 ubiquitin ligases [42], presenting an excellent candidate for future studies on the mechanisms of regulation of muscle atrophy by miRNAs in cachexia. miR-206 and miR-21 were also recently described as having a role in muscle wasting in catabolic conditions [43]. miR-21 has been already confirmed as being produced and exported from tumor cells of rodent and humans and uptaken by the skeletal muscle, in exosomes. The effect of this process is the onset of proteolysis through toll-like receptor 7 signaling, in a JNK dependent manner [44]. Moreover, the detection of aberrant miRNA expression in body fluids, that is, blood, urine, and saliva, opens ways to explore these molecules as diagnostic and prognostic tools for cancer cachexia. miRNAs are also known to play a major role in the regulation of the transcription of several genes involved with key aspects of white adipose tissue metabolism. To date, one study involving cachectic patients, white adipose tissue, and miRNA profile is available in the literature [45]. In this study, five miRNAs showed specific cachexia associated patterns of expression. miR-483-5p/-23a/-744/-99b expression is downregulated and miR-378 is upregulated in cachectic patients. miR-378 is strongly involved with catecholamine-stimulated lipolysis in adipocytes and modulates the expression of key lipolytic proteins such as LIPE, PLIN1, and PNPLa2. No information is available in the literature about miRNAs expression and the modulation of inflammation in the white adipose tissue in specific wasting conditions. However, Xie et al., 2009 [46], demonstrated that a chronic inflammatory environment characterized by high cytokine concentration may, per se, change miRNA pattern expression in the white adipose tissue, both in cultured differentiated adipocytes and in rodent models. Potential miRNA candidates for studies regarding adipose tissue inflammation and cachexia would be miR-155, miR-146a, miR-21, and miR-9, whose expression is induced by the activation of innate immune system through toll-like receptors [47].

6. Conclusion

Considering that miRNAs are known to regulate the expression of genes involved in several types of diseases as cancer and autoimmune disorders [34, 35] and play a pivotal role in the regulation of inflammatory responses, the study of miRNAs in cachexia is a promising field of research, and patients could benefit not only from the development of new targets for treatments, but also from earlier diagnosis. Chronic inflammation in cancer cachexia is a highly complex biological process. The discovery of noncoding RNAs and the improvement of molecular biology techniques have changed the concept that inflammation could be understood and explained by the study of signaling pathways and by the contribution of specific proteins. Knowledge on the regulation of gene and protein expression has changed profoundly, and miRNAs are nowadays established as pivotal components of the signaling networks that modulate inflammatory processes [48], leading to wasting conditions such as cachexia. Based on such evidence, we propose that miRNAs participation in the onset and maintenance of cachexia should be added to the study of the syndrome (Figure 3).

Figure 3: miRNA as part of cachexia modulation as an addition to the Tisdale proposition [8].

Conflict of Interests

The authors declare no conflict of interests.

Acknowledgment

This work was supported by FAPESP no. 2012/50079-0.

References

  1. A. M. Katz and P. B. Katz, “Diseases of the heart in the works of Hippocrates,” British Heart Journal, vol. 24, pp. 257–264, 1962. View at Publisher · View at Google Scholar · View at Scopus
  2. Y. Muliawati, H. Haroen, and L. W. Rotty, “Cancer anorexia—cachexia syndrome,” The Indonesian Journal of Internal Medicine, vol. 44, no. 2, pp. 154–162, 2012. View at Google Scholar
  3. J. M. Argilés, B. Alvarez, and F. J. López-Soriano, “The metabolic basis of cancer cachexia,” Medicinal Research Reviews, vol. 17, no. 5, pp. 477–498, 1997. View at Publisher · View at Google Scholar · View at Scopus
  4. K. C. H. Fearon and A. G. W. Moses, “Cancer cachexia,” International Journal of Cardiology, vol. 85, no. 1, pp. 73–81, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. M. J. Tisdale, “Cancer cachexia,” Current Opinion in Gastroenterology, vol. 26, no. 2, pp. 146–151, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. O. Wallengren, K. Lundholm, and I. Bosaeus, “Diagnostic criteria of cancer cachexia: relation to quality of life, exercise capacity and survival in unselected palliative care patients,” Supportive Care in Cancer, vol. 21, no. 6, pp. 1569–1577, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. J. M. Argilés, S. Busquets, and F. J. López-Soriano, “Cytokines as mediators and targets for cancer cachexia,” Cancer Treatment and Research, vol. 130, pp. 199–217, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. M. J. Tisdale, “Pathogenesis of cancer cachexia,” The Journal of Supportive Oncology, vol. 1, no. 3, pp. 159–168, 2003. View at Google Scholar · View at Scopus
  9. D. C. McMillan, “An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer,” The Proceedings of the Nutrition Society, vol. 67, no. 3, pp. 257–262, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. W. J. Evans, J. E. Morley, J. Argilés et al., “Cachexia: a new definition,” Clinical Nutrition, vol. 27, no. 6, pp. 793–799, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Fearon, F. Strasser, S. D. Anker et al., “Definition and classification of cancer cachexia: an international consensus,” The Lancet Oncology, vol. 12, no. 5, pp. 489–495, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. J. M. Argilés, F. J. López-Soriano, M. Toledo, A. Betancourt, R. Serpe, and S. Busquets, “The cachexia score (CASCO): a new tool for staging cachectic cancer patients,” Journal of Cachexia, Sarcopenia and Muscle, vol. 2, no. 2, pp. 87–93, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Thoresen, G. Frykholm, S. Lydersen et al., “Nutritional status, cachexia and survival in patients with advanced colorectal carcinoma. Different assessment criteria for nutritional status provide unequal results,” Clinical Nutrition, vol. 32, no. 1, pp. 65–72, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Baldwin, “Nutritional support for malnourished patients with cancer,” Current Opinion in Supportive and Palliative Care, vol. 5, no. 1, pp. 29–36, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. J. M. Argilés, R. Moore-Carrasco, S. Busquets, and F. J. López-Soriano, “Catabolic mediators as targets for cancer cachexia,” Drug Discovery Today, vol. 8, no. 18, pp. 838–844, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. K. C. H. Fearon, D. J. Glass, and D. C. Guttridge, “Cancer cachexia: mediators, signaling, and metabolic pathways,” Cell Metabolism, vol. 16, no. 2, pp. 153–166, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. G. Costa, “Cachexia, the metabolic component of neoplastic diseases,” Cancer Research, vol. 37, no. 7, pp. 2327–2335, 1977. View at Google Scholar · View at Scopus
  18. T. Agustsson, P. Wikrantz, M. Rydén, T. Brismar, and B. Isaksson, “Adipose tissue volume is decreased in recently diagnosed cancer patients with cachexia,” Nutrition, vol. 28, no. 9, pp. 851–855, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Bilir, H. Engin, M. Can, Y. B. Temi, and D. Demirtas, “The prognostic role of inflammation and hormones in patients with metastatic cancer with cachexia,” Medical Oncology, vol. 32, p. 497, 2015. View at Google Scholar
  20. M. L. Batista Jr., M. Olivan, P. S. M. Alcantara et al., “Adipose tissue-derived factors as potential biomarkers in cachectic cancer patients,” Cytokine, vol. 61, no. 2, pp. 532–539, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. S.-Y. Suh, Y. S. Choi, C. H. Yeom et al., “Interleukin-6 but not tumour necrosis factor-alpha predicts survival in patients with advanced cancer,” Supportive Care in Cancer, vol. 21, no. 11, pp. 3071–3077, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. E. Tazaki, N. Shimizu, R. Tanaka et al., “Serum cytokine profiles in patients with prostate carcinoma,” Experimental and Therapeutic Medicine, vol. 2, no. 5, pp. 887–891, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. R. W. Carthew and E. J. Sontheimer, “Origins and Mechanisms of miRNAs and siRNAs,” Cell, vol. 136, no. 4, pp. 642–655, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. V. N. Kim, J. Han, and M. C. Siomi, “Biogenesis of small RNAs in animals,” Nature Reviews Molecular Cell Biology, vol. 10, no. 2, pp. 126–139, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Han, Y. Lee, K.-H. Yeom et al., “Molecular basis for the recognition of primary microRNAs by the Drosha-DGCR8 complex,” Cell, vol. 125, no. 5, pp. 887–901, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Khvorova, A. Reynolds, and S. D. Jayasena, “Functional siRNAs and miRNAs exhibit strand bias,” Cell, vol. 115, pp. 209–216, 2003. View at Google Scholar
  27. D. S. Schwarz, G. Hutvágner, T. Du, Z. Xu, N. Aronin, and P. D. Zamore, “Asymmetry in the assembly of the RNAi enzyme complex,” Cell, vol. 115, no. 2, pp. 199–208, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. P. Kharaziha, S. Ceder, Q. Li, and T. Panaretakis, “Tumor cell-derived exosomes: a message in a bottle,” Biochimica et Biophysica Acta, vol. 1826, no. 1, pp. 103–111, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Bang, S. Batkai, S. Dangwal et al., “Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy,” The Journal of Clinical Investigation, vol. 124, no. 5, pp. 2136–2146, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. Y. Yin, J. Li, S. Chen, T. Zhou, and J. Si, “MicroRNAs as diagnostic biomarkers in gastric cancer,” International Journal of Molecular Sciences, vol. 13, no. 10, pp. 12544–12555, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. U. A. Ørom, F. C. Nielsen, and A. H. Lund, “MicroRNA-10a binds the 5′UTR of ribosomal protein mRNAs and enhances their translation,” Molecular Cell, vol. 30, no. 4, pp. 460–471, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Griffiths-Jones, “The microRNA registry,” Nucleic Acids Research, vol. 32, pp. D109–D111, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Lewis and L. Redrup, “Genetic imprinting: conflict at the callipyge locus,” Current Biology, vol. 15, no. 8, pp. R291–R294, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. L. MacDonagh, S. G. Gray, S. P. Finn, S. Cuffe, K. J. O'Byrne, and M. P. Barr, “The emerging role of microRNAs in resistance to lung cancer treatments,” Cancer treatment reviews, vol. 41, no. 2, pp. 160–169, 2015. View at Publisher · View at Google Scholar
  35. A. Carta, R. Chetcuti, and D. Ayers, “An introspective update on the influence of miRNAs in breast carcinoma and neuroblastoma chemoresistance,” Genetics Research International, vol. 2014, Article ID 743050, 2014. View at Publisher · View at Google Scholar
  36. R. Saba, D. L. Sorensen, and S. A. Booth, “MicroRNA-146a: a dominant, negative regulator of the innate immune response,” Frontiers in Immunology, vol. 5, p. 578, 2014. View at Google Scholar
  37. C. Hilton, M. J. Neville, and F. Karpe, “MicroRNAs in adipose tissue: their role in adipogenesis and obesity,” International Journal of Obesity, vol. 37, no. 3, pp. 325–332, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. R. M. O'Connell, “MicroRNAs function on a new level,” Blood, vol. 119, no. 17, pp. 3875–3876, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. K. Hitachi, M. Nakatani, and K. Tsuchida, “Myostatin signaling regulates Akt activity via the regulation of miR-486 expression,” The International Journal of Biochemistry & Cell Biology, vol. 47, no. 1, pp. 93–103, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. J. Wang, Z. Jia, C. Zhang et al., “miR-499 protects cardiomyocytes from H2O2-induced apoptosis via its effects on Pdcd4 and Pacs2,” RNA Biology, vol. 11, no. 4, pp. 339–350, 2014. View at Publisher · View at Google Scholar · View at Scopus
  41. S. A. Reed, P. B. Sandesara, S. M. Senf, and A. R. Judge, “Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy,” FASEB Journal, vol. 26, no. 3, pp. 987–1000, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. J. Xu, R. Li, B. Workeneh, Y. Dong, X. Wang, and Z. Hu, “Transcription factor FoxO1, the dominant mediator of muscle wasting in chronic kidney disease, is inhibited by microRNA-486,” Kidney International, vol. 82, no. 4, pp. 401–411, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. R. J. Soares, S. Cagnin, F. Chemello et al., “Involvement of microRNAs in the regulation of muscle wasting during catabolic conditions,” The Journal of Biological Chemistry, vol. 289, no. 32, pp. 21909–21925, 2014. View at Publisher · View at Google Scholar
  44. W. A. He, F. Calore, P. Londhe, A. Canella, D. C. Guttridge, and C. M. Croce, “Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 12, pp. 4525–4529, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Kulyté, S. Lorente-Cebrián, H. Gao et al., “MicroRNA profiling links miR-378 to enhanced adipocyte lipolysis in human cancer cachexia,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 306, no. 3, pp. E267–E274, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. H. Xie, B. Lim, and H. F. Lodish, “MicroRNAs induced during adipogenesis that accelerate fat cell development are downregulated in obesity,” Diabetes, vol. 58, no. 5, pp. 1050–1057, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. L. A. O'Neill, F. J. Sheedy, and C. E. McCoy, “MicroRNAs: the fine-tuners of Toll-like receptor signalling,” Nature Reviews Immunology, vol. 11, no. 3, pp. 163–175, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. M. P. Boldin and D. Baltimore, “MicroRNAs, new effectors and regulators of NF-κB,” Immunological Reviews, vol. 246, no. 1, pp. 205–220, 2012. View at Publisher · View at Google Scholar · View at Scopus